SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following the appointment of a new COO with deep semiconductor manufacturing expertise, signaling a strategic shift toward scaling high-volume production for AI data center infrastructure. The community is actively discussing the stock's resilience amid broader market volatility, with significant debate focused on the company's massive options volume and the potential for a gamma squeeze as investors bet on future hyperscaler adoption.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors aggressively position themselves ahead of the upcoming first-quarter earnings report, which will be released before the bell on May 14. The community is actively debating the stock's future, balancing optimistic sentiment about revenue growth and recent institutional accumulation against concerns over dilution and persistent share price volatility.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors weigh significant volatility and heavy speculation ahead of the company's upcoming earnings report. The community is actively debating the impact of recent government contract wins, potential institutional interest, and broader space sector momentum driven by the anticipation of a major SpaceX IPO.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is generating significant community buzz as retail investors debate its potential for a short squeeze amid high short interest and recent heavy insider buying. The conversation remains split between those focused on the company's long-term growth and partnerships and those concerned about volatility and macroeconomic pressures.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to a positive earnings print, featuring revenue growth and raised guidance that triggered significant premarket buying interest. The community is actively debating the company's long-term valuation relative to its DefenCath commercialization, the impact of recent institutional buying, and ongoing discussions surrounding Medicare reimbursement strategies.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors react to a significant earnings beat and raised guidance driven by surging demand for its AI infrastructure. The community is actively debating whether this momentum marks a sustainable re-rating of the company as a key AI player or if it mirrors historical tech bubbles, with many traders focused on the stock's recent record-breaking price action and job restructuring news.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing market volatility and increased scrutiny following a clinical hold on its RGX-111 and RGX-121 programs due to a safety finding, which investors are weighing against its upcoming February 8 PDUFA decision. The community remains focused on the potential impact of these regulatory headwinds on the company's long-term pipeline, including its RGX-202 Duchenne gene therapy, while debating whether current price action reflects an overreaction or a fundamental shift in risk.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as investors weigh potential upside from essential home repair demand against broader macroeconomic headwinds like interest rate sensitivity and cooling consumer discretionary spending. The community remains divided, with many traders discussing bullish reversal patterns and institutional call buying, while others express caution regarding the company's guidance and the overall health of the housing market.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber, Inc. is trending as investors react to the company's convertible note offering and its strategic positioning as a key infrastructure partner for Cerebras Systems ahead of a highly anticipated IPO. While some in the community express frustration over past management performance and volatile price action, others are focused on the company's capacity expansion and its potential to benefit from the broader AI data center buildout.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant market attention as investors track the final milestones of its Phase 3 REGAL trial, with the community actively speculating on a potential short squeeze driven by heavy volume and high institutional interest. Sentiment is largely bullish, as shareholders highlight the drug's potential as a paradigm shift in oncology and view the impending data readout as a major catalyst for a valuation rerating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Some analysts just don&#39;t get it. I was a big $WIX bull back in the day (and $FVRR ) but those stories are over. It will take time but they will slowly wilt away like a flower. Sad but true, yet you still have analysts who somehow can&#39;t see it or are blinded by $&#39;s or conflicts of interest: 
 
Barclays analyst Trevor Young lowered the firm&#39;s price target on $WIX  to $100 from $155 and keeps an Overweight rating

StockTwits Web

Wix.com Ltd

Fiverr International Ltd

Some analysts just don't get it. I was a big 

 ) but those stories are over. It will take time but they will slowly wilt away like a flower. Sad but true, yet you still have analysts who somehow can't see it or are blinded by $'s or conflicts of interest: 
 
Barclays analyst Trevor Young lowered the firm's price target on 

  to $100 from $155 and keeps an Overweight rating